At Fluxion, we’re passionate about delivering cell-based and cell-free solutions that facilitate the transformation of research discoveries into new ways to diagnose and treat patients. By characterizing molecular and cellular mechanisms of disease, Fluxion’s platforms help bridge the translational medicine gap, enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests.
Dr. Andrew Jenkins Ph.D, Associate Professor, Faculty of Pharmacy & Pharmaceutical Sciences, Emory University School of Medicine
It is well known that the GABA(A) receptor is the primary target for the therapeutic actions of benzodiazepines and for many general anesthetics. Both groups of compounds act as GABA(A) receptor positive allosteric modulators (GABAPAMs), increasing the strength of phasic and tonic inhibition in the brain. This seminar will explore our use of conventional and microfluidic electrophysiology in translational research projects that have led us to the discovery of novel endogenous GABAPAMs and new disease mechanisms.